Heart failure (HF) is one of the most common causes of hospital admission in Canada and costs the Canadian healthcare system over $1 billion annually. Influenza vaccination is an inexpensive strategy to prevent influenza infections and reduce an important trigger for HF decompensation and hospital readmission. Yet, the optimal timing of vaccine administration remains unclear. When patients with HF are admitted to the hospital with an acute decompensation in advance of, or during, the 'flu season', this can be an ideal time to administer the vaccine. However, patients with acute HF decompensation have significant inflammatory injury, and may have substantially impaired immune responses; thus vaccine administration while admitted during an acute decompensated HF episode may not lead to high anti-influenza antibody titres. A more effective strategy can be to vaccinate after the decompensation has resolved, when patients are more stable. The FLU-HF randomized trial will determine whether administering the influenza vaccine to patients admitted in-hospital with an acute HF decompensation or waiting until they have stabilized as an out-patient leads to an improved anti-influenza response.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
McGill University Health Centre
Montreal, Quebec, Canada
RECRUITINGSeroconversion for one or more strains in the influenza vaccine one month following vaccination.
Seroconversion will be measured by antibody as assessed by the hemagglutination inhibition (HI) assay.
Time frame: Randomization to one month post randomization
Change in NTproBNP
Serologic blood work measured at randomization and post-randomization
Time frame: Randomization to one month post randomization
Change in high-sensitivity troponin
Serologic blood work measured at randomization and post-randomization
Time frame: Randomization to one month post randomization
Changes in inflammatory markers
Inflammatory markers as measured by HsCRP, IL1, IL6, at randomization and post-randomization
Time frame: Randomization to one month post randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.